A phase 1 Bayesian dose selection study of bortezomib and sunitinib in patients with refractory solid tumor malignancies

BACKGROUND: This phase 1 trial utilising a Bayesian continual reassessment method evaluated bortezomib and sunitinib to determine the maximum tolerated dose (MTD), dose-limiting toxicities (DLT), and recommended doses of the combination. METHODS: Patients with advanced solid organ malignancies were...

Descripción completa

Detalles Bibliográficos
Autores principales: Harvey, R D, Owonikoko, T K, Lewis, C M, Akintayo, A, Chen, Z, Tighiouart, M, Ramalingam, S S, Fanucchi, M P, Nadella, P, Rogatko, A, Shin, D M, El-Rayes, B, Khuri, F R, Kauh, J S
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2013
Materias:
Short Communication
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3590658/
https://www.ncbi.nlm.nih.gov/pubmed/23322195
http://dx.doi.org/10.1038/bjc.2012.604

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3590658/
https://www.ncbi.nlm.nih.gov/pubmed/23322195
http://dx.doi.org/10.1038/bjc.2012.604

Ejemplares similares